Cancer revoked: oncogenes as therapeutic targets

被引：287
作者：
Felsher, DW
机构：
[1] Stanford Univ, Div Oncol, Dept Med, Stanford, CA 94305 USA
[2] Stanford Univ, Div Oncol, Dept Pathol, Stanford, CA 94305 USA
来源：
NATURE REVIEWS CANCER | 2003年 / 3卷 / 05期
关键词：
D O I：
10.1038/nrc1070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent findings show that even the brief inactivation of a single oncogene might be sufficient to result in the sustained loss of a neoplastic phenotype. It is therefore possible that the targeted inactivation of oncogenes could be a specific and effective treatment for cancer So why does oncogene inactivation cause tumour regression and will this be a generally successful approach for the treatment of human neoplasia?.
引用
收藏
页码：375 / 380
页数：6
相关论文
共 37 条
  • [1] Role of DNA 5-methylcytosine transferase in cell transformation by fos
    Bakin, AV
    Curran, T
    [J]. SCIENCE, 1999, 283 (5400) : 387 - 390
  • [2] c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression
    Baudino, TA
    McKay, C
    Pendeville-Samain, H
    Nilsson, JA
    Maclean, KH
    White, EL
    Davis, AC
    Ihle, JN
    Cleveland, JL
    [J]. GENES & DEVELOPMENT, 2002, 16 (19) : 2530 - 2543
  • [3] Medulloblastoma growth inhibition by Hedgehog pathway blockade
    Berman, DM
    Karhadkar, SS
    Hallahan, AR
    Pritchard, JI
    Eberhart, CG
    Watkins, DN
    Chen, JK
    Cooper, MK
    Taipale, J
    Olson, JM
    Beachy, PA
    [J]. SCIENCE, 2002, 297 (5586) : 1559 - 1561
  • [4] INFECTION OF CHICK LIMB BUD PRESUMPTIVE CHONDROBLASTS BY A TEMPERATURE-SENSITIVE MUTANT OF ROUS-SARCOMA VIRUS AND THE REVERSIBLE INHIBITION OF THEIR TERMINAL DIFFERENTIATION IN CULTURE
    BOETTIGER, D
    SOLTESZ, R
    HOLTZER, H
    PACIFICI, M
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1983, 3 (08) : 1518 - 1526
  • [5] Essential role for oncogenic Ras in tumour maintenance
    Chin, L
    Tam, A
    Pomerantz, J
    Wong, M
    Holash, J
    Bardeesy, N
    Shen, Q
    O'Hagan, R
    Pantginis, J
    Zhou, H
    Horner, JW
    Cordon-Cardo, C
    Yancopoulos, GD
    DePinho, RA
    [J]. NATURE, 1999, 400 (6743) : 468 - 472
  • [6] c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
    D'Cruz, CM
    Gunther, EJ
    Boxer, RB
    Hartman, JL
    Sintasath, L
    Moody, SE
    Cox, JD
    Ha, SI
    Belka, GK
    Golant, A
    Cardiff, RD
    Chodosh, LA
    [J]. NATURE MEDICINE, 2001, 7 (02) : 235 - 239
  • [7] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD
    von Mehren, M
    Blanke, CD
    Van den Abbeele, AD
    Eisenberg, B
    Roberts, PJ
    Heinrich, MC
    Tuveson, DA
    Singer, S
    Janicek, M
    Fletcher, JA
    Silverman, SG
    Silberman, SL
    Capdeville, R
    Kiese, B
    Peng, B
    Dimitrijevic, S
    Druker, BJ
    Corless, C
    Fletcher, CDM
    Joensuu, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 472 - 480
  • [8] Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
    Di Croce, L
    Raker, VA
    Corsaro, M
    Fazi, F
    Fanelli, M
    Faretta, M
    Fuks, F
    Lo Coco, F
    Kouzarides, T
    Nervi, C
    Minucci, S
    Pelicci, PG
    [J]. SCIENCE, 2002, 295 (5557) : 1079 - 1082
  • [9] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Druker, BJ
    Talpaz, M
    Resta, DJ
    Peng, B
    Buchdunger, E
    Ford, JM
    Lydon, NB
    Kantarjian, H
    Capdeville, R
    Ohno-Jones, S
    Sawyers, CL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1031 - 1037
  • [10] Esteller M, 2002, SCIENCE, V297, P1807
1234